Lieve Brochez

List of Publications by Year
in descending order

95 papers	3,119 citations	126708 33 h-index	168136 53 g-index
100 all docs	100 docs citations	100 times ranked	5457 citing authors

#	Article	IF	Citations
1	Basal cell carcinoma in older adults: how to decide when active surveillance or watchful waiting is appropriate?. British Journal of Dermatology, 2022, 187, 244-245.	1.4	4
2	The value of measuring uncertainty in neural networks in dermoscopy. Journal of the American Academy of Dermatology, 2022, , .	0.6	0
3	Skin Cancer Detection Using Infrared Thermography: Measurement Setup, Procedure and Equipment. Sensors, 2022, 22, 3327.	2.1	22
4	Health state utility instruments in patients with keratinocyte cancer and actinic keratosis: a crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	3
5	Lesionâ€directed screening to optimize skin cancer detection in dermatology practice: an observational study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1309-1314.	1.3	5
6	Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial. BMC Cancer, 2021, 21, 514.	1.1	10
7	Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures. Cancers, 2021, 13, 2630.	1.7	3
8	Three-dimensional margin assessment in head and neck malignancies using a submillimetric 18F-FDG PET/CT, results of an ongoing clinical trial. Oral Oncology, 2021, 118, 5.	0.8	0
9	High-Resolution 18F-FDG PET/CT for Assessing Three-Dimensional Intraoperative Margins Status in Malignancies of the Head and Neck, a Proof-of-Concept. Journal of Clinical Medicine, 2021, 10, 3737.	1.0	13
10	26915 Steps towards trustworthy AI: Detecting unsupported lesions. Journal of the American Academy of Dermatology, 2021, 85, AB26.	0.6	1
11	Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNÎ³-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma. Frontiers in Immunology, 2021, 12, 736498.	2.2	8
12	Dynamic Infrared Thermography (DIRT) in Biomedical Applications: DIEP Flap Breast Reconstruction and Skin Cancer. Engineering Proceedings, 2021, 8, 3.	0.4	1
13	Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 789473.	2.2	2
14	IDO Expression in Cancer: Different Compartment, Different Functionality?. Frontiers in Immunology, 2020, 11, 531491.	2.2	104
15	Recommendations for skin cancer consultation and surgery during COVIDâ€19 pandemic. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1876-1878.	1.3	6
16	The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype. Cancer Research, 2020, 80, 2983-2995.	0.4	51
17	A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunology, Immunotherapy, 2020, 69, 2589-2598.	2.0	44
18	Enhanced visualization of blood and pigment in multispectral skin dermoscopy. Skin Research and Technology, 2020, 26, 708-712.	0.8	10

#	Article	IF	Citations
19	Charting Extracellular Transcriptomes in The Human Biofluid RNA Atlas. Cell Reports, 2020, 33, 108552.	2.9	50
20	Abstract PR15: Charting extracellular transcriptomes in The Human Biofluid RNA Atlas. , 2020, , .		0
21	Haptoglobin polymorphism and the risk of actinic keratoses and cutaneous squamous cell carcinoma: A caseâ€“control study. Journal of Dermatology, 2019, 46, 274-275.	0.6	2
22	Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. European Urology, 2019, 75, 707-711.	0.9	89
23	Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma. International Journal of Radiation Oncology Biology Physics, 2019, 104, 828-835.	0.4	46
24	Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?. Current Opinion in Oncology, 2019, 31, 54-64.	1.1	66
25	Value of Dermoscopy in a Population-Based Screening Sample by Dermatologists. Dermatology Practical and Conceptual, 2019, 9, 200-206.	0.5	7
26	Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results.. Journal of Clinical Oncology, 2019, 37, 422-422.	0.8	0
27	A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma. Neoplasia, 2018, 20, 218-225.	2.3	31
28	Phase 1 Dose Escalation Trial of Ipilimumab andÂStereotactic Body Radiation Therapy in Metastatic Melanoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 906-915.	0.4	30
29	A CARD9 Founder Mutation Disrupts NF-Î¹B Signaling by Inhibiting BCL10 and MALT1 Recruitment and Signalosome Formation. Frontiers in Immunology, 2018, 9, 2366.	2.2	46
30	Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review. Case Reports in Dermatology, 2018, 10, 190-197.	0.3	54
31	OC-0682: Phase 1 trial of pembrolizumab with SBRT in metastatic urothelial carcinoma. Radiotherapy and Oncology, 2018, 127, S357-S358.	0.3	1
32	Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma. Nature Communications, 2018, 9, 2921.	5.8	26
33	Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile. Oncotarget, 2018, 9, 25216-25224.	0.8	26
34	A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. Journal of Translational Medicine, 2017, 15, 21.	1.8	21
35	The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. European Journal of Cancer, 2017, 76, 167-182.	1.3	234
36	Cost-effectiveness and Budget Effect Analysis of a Population-Based Skin Cancer Screening. JAMA Dermatology, 2017, 153, 147.	2.0	21

#	Article	IF	Citations
37	Pathologic Evaluation of Skin Tumors With Ex Vivo Dermoscopy With Derm Dotting. JAMA Dermatology, 2017, 153, 154.	2.0	9
38	OC-0017: Combined High Dose Radiation and Ipilimumab in Metastatic Melanoma, a Phase I Dose Escalation Trial. Radiotherapy and Oncology, 2017, 123, S5.	0.3	0
39	Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. European Journal of Cancer, 2017, 86, 358-363.	1.3	72
40	A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. Journal of Translational Medicine, 2017, 15, 150.	1.8	26
41	Successful strategy to treat a solitary cystic melanoma brain metastasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e216-e217.	1.3	0
42	Phase II study of ipilimumab (IPI) in children and adolescents with unresectable stage III or IV malignant melanoma (MEL).. Journal of Clinical Oncology, 2017, 35, e21006-e21006.	0.8	1
43	Long non-coding RNAs in cutaneous melanoma: clinical perspectives. Oncotarget, 2017, 8, 43470-43480.	0.8	35
44	Systemic treatment influences on immune accessibility of melanoma: A retrospective histopathological investigation. Annals of Oncology, 2016, 27, vi388.	0.6	0
45	Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening. British Journal of Dermatology, 2016, 174, 1258-1265.	1.4	56
46	Successful Treatment of HCV-associated B-Cell Non-Hodgkin Lymphomas With Direct-acting Antiviral Agents. Journal of Clinical Gastroenterology, 2016, 50, 438.	1.1	3
47	Burden of skin cancer in Belgium and cost-effectiveness of primary prevention by reducing ultraviolet exposure. Preventive Medicine, 2016, 93, 177-182.	1.6	34
48	Chemoprevention of basal cell carcinoma: reply from authors. British Journal of Dermatology, 2016, , .	1.4	0
49	Chemoprevention of basal cell carcinoma: reply from authors. British Journal of Dermatology, 2016, 175, 1404-1405.	1.4	0
50	Chronic and Invasive Fungal Infections in a Family with CARD9 Deficiency. Journal of Clinical Immunology, 2016, 36, 204-209.	2.0	98
51	Comparison of Ex Vivo and In Vivo Dermoscopy in Dermatopathologic Evaluation of Skin Tumors. JAMA Dermatology, 2016, 152, 312.	2.0	10
52	Total-Body Examination vs Lesion-Directed Skin Cancer Screening. JAMA Dermatology, 2016, 152, 27.	2.0	51
53	Rosettes and other white shiny structures in polarized dermoscopy: histological correlate and optical explanation. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 311-313.	1.3	47
54	Systemic immune changes associated with adjuvant interferon-Î±2b-therapy in stage III melanoma patients. Melanoma Research, 2015, 25, 357-361.	0.6	13

#	Article	IF	Citations
55	Phase I trial of stereotactic body radiotherapy with concurrent fixed dose ipilimumab in metastatic melanoma: Dose limiting toxicity and abscopal effect. Annals of Oncology, 2015, 26, viii5.	0.6	0
56	Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. Journal of Translational Medicine, 2015, 13, 9.	1.8	54
57	A short dermoscopy training increases diagnostic performance in both inexperienced and experienced dermatologists. Australasian Journal of Dermatology, 2015, 56, 52-55.	0.4	17
58	Characterization of thein vivoimmune network of IDO, tryptophan metabolism, PD-L1, andCTLA-4in circulating immune cells in melanoma. OncoImmunology, 2015, 4, e982382.	2.1	95
59	Efficacy of Products to Remove Eggs of <I>Pediculus humanus capitis</I> (Phthiraptera: Pediculidae) From the Human Hair. Journal of Medical Entomology, 2014, 51, 400-407.	0.9	12
60	Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. Endocrine, 2014, 47, 878-883.	1.1	37
61	Peritumoral indoleamine 2,3â€dioxygenase expression in melanoma: an early marker of resistance to immune control?. British Journal of Dermatology, 2014, 171, 987-995.	1.4	63
62	Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 741-746.	1.3	39
63	Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death and Differentiation, 2014, 21, 1250-1261.	5.0	195
64	A crossâ€sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 507-511.	1.3	30
65	Cancer risk in immune-mediated inflammatory diseases (IMID). Molecular Cancer, 2013, 12, 98.	7.9	104
66	The distribution pattern of segmental vitiligo: clues for somatic mosaicism. British Journal of Dermatology, 2013, 168, 56-64.	1.4	33
67	miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. International Journal of Oncology, 2013, 42, 1443-1451.	1.4	76
68	Clinical significance of Koebner phenomenon in vitiligo. British Journal of Dermatology, 2012, 167, 1017-1024.	1.4	25
69	In vivo vitiligo induction and therapy model: doubleâ€blind, randomized clinical trial. Pigment Cell and Melanoma Research, 2012, 25, 57-65.	1.5	36
70	Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. European Journal of Cancer, 2012, 48, 2004-2011.	1.3	92
71	Immune mediated mechanisms of melanocyte destruction. OncoImmunology, 2012, 1, 526-528.	2.1	4
72	The haptoglobin phenotype influences the risk of cutaneous squamous cell carcinoma in kidney transplant patients. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 566-571.	1.3	12

#	Article	IF	Citations
73	Halo naevi with associated vitiligoâ€like depigmentations: pathogenetic hypothesis. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 755-761.	1.3	18
74	New insights in segmental vitiligo: case report and review of theories. British Journal of Dermatology, 2012, 166, 240-246.	1.4	61
75	Three-dimensional skin models as tools for transdermal drug delivery: challenges and limitations. Expert Opinion on Drug Delivery, 2011, 8, 705-720.	2.4	68
76	Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. Pigment Cell and Melanoma Research, 2011, 24, 334-344.	1.5	45
77	P032. Indoleamine 2,3 dioxygenase. Melanoma Research, 2011, 21, e34.	0.6	0
78	P069. The haptoglobin phenotype influences the risk of cutaneous squamous cell carcinoma in kidney transplant patients. Melanoma Research, 2011, 21, e55.	0.6	0
79	Prognostic value and clinical significance of halo naevi regarding vitiligo. British Journal of Dermatology, 2011, 164, 743-749.	1.4	31
80	Different phenotypes of segmental vitiligo based on a clinical observational study. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 673-678.	1.3	31
81	EGFR in melanoma: clinical significance and potential therapeutic target. Journal of Cutaneous Pathology, 2011, 38, 492-502.	0.7	77
82	Association of haptoglobin phenotypes with the development of Kaposiâ€™s sarcoma in HIV patients. Archives of Dermatological Research, 2011, 303, 763-769.	1.1	10
83	Dermatological side effects of current and upcoming targeted therapies in oncology. Acta Clinica Belgica, 2011, 66, 97-103.	0.5	6
84	Acute generalized exanthematous pustulosis: anÂoverview ofÂtheÂclinical, immunological andÂdiagnostic concepts. European Journal of Dermatology, 2010, 20, 425-433.	0.3	93
85	P-cadherin counteracts myosin II-B function: implications in melanoma progression. Molecular Cancer, 2010, 9, 255.	7.9	19
86	Superficial granulomatous pyoderma with ocular involvement. European Journal of Dermatology, 2010, 20, 648-9.	0.3	0
87	The role of RhoC in growth and metastatic capacity of melanoma. Journal of Cutaneous Pathology, 2009, 36, 629-636.	0.7	31
88	Clinical significance of the expression of c-Ski and SnoN, possible mediators in TGF-Î² resistance, in primary cutaneous melanoma. Journal of Dermatological Science, 2009, 53, 26-33.	1.0	23
89	The role of VEGF-C staining in predicting regional metastasis in melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 257-265.	1.4	46
90	Incidence of scabies in Belgium. Epidemiology and Infection, 2008, 136, 395-398.	1.0	18

#	Article	IF	Citations
91	Dysplastic Nevi. New England Journal of Medicine, 2003, 349, 2233-2240.	13.9	90
92	The melanoma burden in Belgium; premature morbidity and mortality make melanoma a considerable health problem. Melanoma Research, 1999, 9, 614-618.	0.6	17
93	Hypomelanoses Associated with Melanocytic Neoplasia. , 0, , 705-724.		2
94	Charting Extracellular Transcriptomes in the Human Biofluid RNA Atlas. SSRN Electronic Journal, 0, , .	0.4	4
95	Randomized Phase 1 Trial of Pembrolizumab with Neo-Adjuvant Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0